Contact Us
Drug Search Results
More Filters [+]

Lonafarnib

Alternative Names: lonafarnib, sarasar, sch 66336, sch66336, zokinvy
Latest Update: 2025-01-14
Latest Update Note: Clinical Trial Update

Product Description

Lonafarnib is an oral, small molecule inhibitor of farnesyltransferase that is used to treat Hutchison-Gilford progeria syndrome and is under investigation as therapy of chronic hepatitis D.  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Lonafarnib)

Mechanisms of Action: FT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Belgium | Croatia | Czech | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Poland | Portugal | Slovakia | Sweden | United States

Approved Indications: Progeria

Known Adverse Events: Hypertension | Abdominal Pain | Headache | Pain Unspecified | Musculoskeletal Pain | Diarrhea

Company: Eiger BioPharmaceuticals
Company Location: PALO ALTO CA 94306
Company CEO: David A. Cory
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lonafarnib

Countries in Clinic: Belgium, Bulgaria, Canada, France, Germany, Greece, Israel, Italy, Moldova, Mongolia, New Zealand, Pakistan, Romania, Russia, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Hepatitis A|Hepatitis D|Hepatitis D, Chronic|Hepatocellular Carcinoma|Liver Cirrhosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
LOWR6

P3

Active, not recruiting

Hepatitis A|Hepatitis D, Chronic

2024-12-31

D-LIVR

P3

Active, not recruiting

Liver Cirrhosis|Hepatocellular Carcinoma

2023-01-24

D-LIVR

P3

Completed

Hepatitis D

2022-10-06

46%

Recent News Events

Date

Type

Title

09/25/2024

News Article

 Septerna Marks Transition to a Clinical-Stage Company with Appointments of Industry Veterans in Key Drug Development Roles

05/03/2024

News Article

 Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals

04/01/2024

News Article

 Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection

03/26/2024

News Article

 The Progeria Research Foundation Selected as an Official Charity Partner in 2024 Boston Marathon

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions